Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial by Lear JT, Hauschild A, Stockfleth E, Squittieri N, Basset-Seguin N, Dummer R

Get full text

Proteinase-activated receptors 1 and 2 activate protein kinase D1 in human melanoma cells by Dummer R, Haußer A, Hoek KS, Bocheva GS, Rattenholl A, Kempkes C, Steinhoff M

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study by Dummer, R, Robert, C, Chapman, P, Sosman, J, Middleton, M, Bastholt, L, Kemsley, K, Cantarini, M, Morris, C, Kirkwood, J

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. by Kirkwood, J, Bastholt, L, Robert, C, Sosman, J, Larkin, J, Hersey, P, Middleton, M, Cantarini, M, Zazulina, V, Kemsley, K, Dummer, R

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. by Robert, C, Dummer, R, Gutzmer, R, Lorigan, P, Kim, K, Nyakas, M, Arance, A, Liszkay, G, Schadendorf, D, Cantarini, M, Spencer, S, Middleton, MR

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study by Robert, C, Dummer, R, Gutzmer, R, Lorigan, P, Kim, K, Nyakas, M, Arance, A, Liszkay, G, Schadendorf, D, Cantarini, M, Spencer, S, Middleton, MR

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. by Goldinger, S, Dummer, R, Baumgaertner, P, Mihic-Probst, D, Schwarz, K, Hammann-Haenni, A, Willers, J, Geldhof, C, Prior, J, Kündig, T, Michielin, O, Bachmann, M, Speiser, D

Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. by Speiser, D, Schwarz, K, Baumgaertner, P, Manolova, V, Devevre, E, Sterry, W, Walden, P, Zippelius, A, Conzett, K, Senti, G, Voelter, V, Cerottini, J, Guggisberg, D, Willers, J, Geldhof, C, Romero, P, Kündig, T, Knuth, A, Dummer, R, Trefzer, U, Bachmann, M

Improved survival with MEK inhibition in BRAF-mutated melanoma. by Flaherty, K, Robert, C, Hersey, P, Nathan, P, Garbe, C, Milhem, M, Demidov, L, Hassel, J, Rutkowski, P, Mohr, P, Dummer, R, Trefzer, U, Larkin, J, Utikal, J, Dreno, B, Nyakas, M, Middleton, M, Becker, J, Casey, M, Sherman, L, Wu, F, Ouellet, D, Martin, A, Patel, K, Schadendorf, D

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours by Melero, I, de Miguel Luken, M, de Velasco, G, Garralda, E, Martín-Liberal, J, Joerger, M, Alonso, G, Goebeler, M, Schuler, M, König, D, Dummer, R, Reig, M, Rodriguez Ruiz, M, Calvo, E, Esteban-Villarrubia, J, Oberoi, A, Sabat, P, Soto-Castillo, JJ, Koster, K, Saavedra, O, Sayehli, C, Gromke, T, Läubli, H, Ramelyte, E

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines by Peris, K, Fargnoli, MC, Garbe, C, Kaufmann, R, Bastholt, L, Seguin, NB, Bataille, V, Marmol, VD, Dummer, R, Harwood, CA, Hauschild, A, Höller, C, Haedersdal, M, Malvehy, J, Middleton, MR, Morton, CA, Nagore, E, Stratigos, AJ, Szeimies, RM, Tagliaferri, L, Trakatelli, M, Zalaudek, I, Eggermont, A, Grob, JJ, European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC)